Data sources and applied methods for paclitaxel safety signal discernment

Public Deposited
Analytics

Downloadable Content

Download PDF
Request Version for Screen Reader
Creator
  • Gressler, Laura Elisabeth
    • Other Affiliation: United States Food and Drug Administration
  • Avila-Tang, Erika
    • Other Affiliation: United States Food and Drug Administration
  • Mao, Jialin
  • Avalos-Pacheco, Alejandra
  • Shaya, Fadia T.
  • Torosyan, Yelizaveta
    • Other Affiliation: United States Food and Drug Administration
  • Liebeskind, Alexander
    • Other Affiliation: United States Food and Drug Administration
  • Kinard, Madris
    • Other Affiliation: Device Events
  • Mack, Christina D.
    • Affiliation: Gillings School of Global Public Health, Department of Epidemiology
  • Normand, Sharon-Lise
    • Other Affiliation: Harvard Medical School
  • Ritchey, Mary E.
    • Other Affiliation: Rutgers University
  • Marinac-Dabic, Danica
    • Other Affiliation: United States Food and Drug Administration
Abstract
  • Background Following the identification of a late mortality signal, the Food and Drug Administration (FDA) convened an advisory panel that concluded that additional clinical study data are needed to comprehensively evaluate the late mortality signal observed with the use of drug-coated balloons (DCB) and drug-eluting stent (DES). The objective of this review is to (1) identify and summarize the existing clinical and cohort studies assessing paclitaxel-coated DCBs and DESs, (2) describe and determine the quality of the available data sources for the evaluation of these devices, and (3) present methodologies that can be leveraged for proper signal discernment within available data sources. Methods Studies and data sources were identified through comprehensive searches. original research studies, clinical trials, comparative studies, multicenter studies, and observational cohort studies written in the English language and published from January 2007 to November 2021, with a follow-up longer than 36 months, were included in the review. Data quality of available data sources identified was assessed in three groupings. Moreover, accepted data-driven methodologies that may help circumvent the limitations of the extracted studies and data sources were extracted and described. Results There were 39 studies and data sources identified. This included 19 randomized clinical trials, nine single-arm studies, eight registries, three administrative claims, and electronic health records. Methodologies focusing on the use of existing premarket clinical data, the incorporation of all contributed patient time, the use of aggregated data, approaches for individual-level data, machine learning and artificial intelligence approaches, Bayesian approaches, and the combination of various datasets were summarized. Conclusion Despite the multitude of available studies over the course of eleven years following the first clinical trial, the FDA-convened advisory panel found them insufficient for comprehensively assessing the late-mortality signal. High-quality data sources with the capabilities of employing advanced statistical methodologies are needed to detect potential safety signals in a timely manner and allow regulatory bodies to act quickly when a safety signal is detected.
Date of publication
Keyword
DOI
Identifier
Resource type
  • Article
Rights statement
  • In Copyright
License
  • Attribution 4.0 International
Journal title
  • Frontiers in Cardiovascular Medicine
Journal volume
  • 10
Language
  • English
Version
  • Publisher
ISSN
  • 2297-055X
Publisher
  • Frontiers

Relations

Parents:

This work has no parents.

In Collection:

Items

Thumbnail Title Date Uploaded Visibility Actions
file details fcvm-10-1331142.pdf 2024-03-04 Public Download